Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H27NO9 |
Molecular Weight | 461.4618 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O[C@]6([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)=CC=C3O
InChI
InChIKey=GNJCUHZOSOYIEC-GAROZEBRSA-N
InChI=1S/C23H27NO9/c1-24-7-6-23-10-3-5-13(31-22-17(28)15(26)16(27)19(33-22)21(29)30)20(23)32-18-12(25)4-2-9(14(18)23)8-11(10)24/h2-5,10-11,13,15-17,19-20,22,25-28H,6-8H2,1H3,(H,29,30)/t10-,11+,13-,15-,16-,17+,19-,20-,22+,23-/m0/s1
Molecular Formula | C23H27NO9 |
Molecular Weight | 461.4618 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Morphine-6-glucuronide is a pharmacologically active metabolite of morphine that is being developed by CeNeS Pharmaceuticals as an alternative to morphine for the management of postoperative pain. Compared to morphine, Morphine-6-glucuronide has been reported to have6 and 86 times lower affinity for the human mu and kappa opioid receptors, respectively, and similar affinity for the delta opioid receptor. Morphine-6-glucuronide is was studied in phase III clinical trials for postoperative pain management. Unfortunately, Morphine-6-glucuronide failed to demonstrate superior safety compared to Morphine and further development was discontinued. Morphine-6-glucuronide accumulates after administration of morphine to patients with renal insufficiency, and analgesia can be obtained with lower doses of morphine compared to patients with normal renal function. More importantly, the dose should be reduced to avoid serious side-effects, although the simulations in this review did not account for side-effects.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Identifying potential binding modes and explaining partitioning behavior using flexible alignments and multidimensional scaling. | 2001 Dec |
|
Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. | 2001 Dec |
|
The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. | 2001 Dec |
|
Limited phase I study of morphine-3-glucuronide. | 2001 Nov |
|
Ultrafast liquid chromatography/tandem mass spectrometry bioanalysis of polar analytes using packed silica columns. | 2002 |
|
Dracunculus medinensis and Schistosoma mansoni contain opiate alkaloids. | 2002 Apr |
|
The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. | 2002 Apr |
|
Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. | 2002 Apr |
|
Quantitative gas chromatographic/mass spectrometric analysis of morphine glucuronides in human plasma by negative ion chemical ionization mass spectrometry. | 2002 Apr |
|
Intranasal delivery of morphine. | 2002 Apr |
|
Verapamil decreases glucuronidase activity in the gut. | 2002 Apr 15 |
|
Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. | 2002 Aug |
|
Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. | 2002 Aug |
|
The influence of inhibition of probenecid sensitive transporters on the central nervous system (CNS) uptake and the antinociceptive activity of morphine-6-glucuronide in rats. | 2002 Aug 30 |
|
Unwanted effects of morphine-6-glucoronide and morphine. | 2002 Dec |
|
Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. | 2002 Dec |
|
Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation. | 2002 Feb |
|
Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment. | 2002 Feb |
|
Increased plasma morphine metabolites in terminally ill cancer patients with delirium: an intra-individual comparison. | 2002 Feb |
|
Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers. | 2002 Feb 27 |
|
Cold stress alters Mytilus edulis pedal ganglia expression of mu opiate receptor transcripts determined by real-time RT-PCR and morphine levels. | 2002 Feb 28 |
|
A phase I/II study of nebulized morphine-6-glucuronide in patients with cancer-related breathlessness. | 2002 Jan |
|
Morphine in cancer pain management: a practical guide. | 2002 Jan |
|
The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. | 2002 Jan |
|
A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. | 2002 Jan |
|
Colostrum morphine concentrations during postcesarean intravenous patient-controlled analgesia. | 2002 Jan |
|
Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. | 2002 Mar |
|
Morphine 6 glucuronide stimulates nitric oxide release in mussel neural tissues: evidence for a morphine 6 glucuronide opiate receptor subtype. | 2002 Mar |
|
Differential antagonism of endomorphin-1 and endomorphin-2 supraspinal antinociception by naloxonazine and 3-methylnaltrexone. | 2002 May |
|
Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. | 2002 May |
|
Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity. | 2002 Nov |
|
Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. | 2002 Oct |
|
Randomized, double-blind, placebo-controlled study of the effect of rectal paracetamol on morphine consumption after abdominal hysterectomy. | 2003 Apr |
|
Rapid and simple method to determine morphine and its metabolites in rat plasma by liquid chromatography-mass spectrometry. | 2003 Apr 25 |
|
Gateways to clinical trials. | 2003 Dec |
|
Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. | 2003 Dec |
|
Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. | 2003 Jan |
|
[Development of opioid tolerance -- molecular mechanisms and clinical consequences]. | 2003 Jan |
|
Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients. | 2003 Jul |
|
The pharmacokinetics of the interstitial space in humans. | 2003 Jul 30 |
|
A novel metabolic pathway of morphine: formation of morphine glucosides in cancer patients. | 2003 Jun |
|
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. | 2003 Jun |
|
Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. | 2003 Mar |
|
Encapsulation of an intrathecal catheter. | 2003 May |
|
Age- and therapy-related effects on morphine requirements and plasma concentrations of morphine and its metabolites in postoperative infants. | 2003 May |
|
High levels of morphine-6-glucuronide in street heroin addicts. | 2003 Nov |
|
Different distribution of morphine and morphine-6 beta-glucuronide after intracerebroventricular injection in rats. | 2003 Sep |
|
Development and validation of a liquid chromatography-mass spectrometry assay for the determination of opiates and cocaine in meconium. | 2003 Sep 5 |
|
Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. | 2004 Feb |
|
Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. | 2004 Jan |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 23:20:39 UTC 2023
by
admin
on
Thu Jul 06 23:20:39 UTC 2023
|
Record UNII |
64Y9KYM60R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000143116
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
SUB118806
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
C166899
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
DB06409
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
64Y9KYM60R
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
5360621
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
CHEMBL611421
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
MORPHINE-6-GLUCURONIDE
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
DTXSID40174158
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
20290-10-2
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY | |||
|
8377
Created by
admin on Thu Jul 06 23:20:40 UTC 2023 , Edited by admin on Thu Jul 06 23:20:40 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|